晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.011

Abstract

Abstract: In recent years,great progress has been made in the treatment of metastatic or locally advanced non-small cell lung cancer,especially for patients who have progressed after first-line therapy or treatment.Improving efficacy through combination therapy has become the main direction in this field,and this exploration is particularly urgent for patients who do not have drive gene mutations or are ineffective against targeted therapy.Evidence that pro-angiogenic factors have immunosuppressive activity led researchers to evaluate potential synergistic effects of anti-angiogenic drugs in combination with immune checkpoint inhibitors in advanced non-small cell lung cancer.This article reviews the theoretical basis and clinical research of anti-angiogenic drugs combined with immune checkpoint inhibitors in the treatment of advanced non-small cell lung cancer.

Key words: Non-small cell lung cancer, Anti-angiogenic therapy, Immune checkpoint inhibitors

CLC Number:

R734.2

DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer[J]. Journal of Practical Oncology, 2022, 36(4): 351-355.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/351

References

1 Topalian SL,Hodi FS,Brahmer JR,et al.Five-year survival and correlates among patients with advanced melanoma,renal cell carcinoma,or non-small cell lung cancer treated with nivolumab[J].JAMA Oncol,2019,5(10):1411-1420.
2 Sharma P,Hu-Lieskovan S,Wargo JA,et al.Primary,adaptive,and acquired resistance to cancer immunotherapy[J].Cell,2017,168(4):707-723.
3 Jenkins RW,Barbie DA,Flaherty KT.Mechanisms of resistance to immune checkpoint inhibitors[J].Br J Cancer,2018,118(1):9-16.
4 Huang Y,Goel S,Duda DG,et al.Vascular normalization as an emerging strategy to enhance cancer immunotherapy[J].Cancer Res,2013,73(10):2943-2948.
5 Ramjiawan RR,Griffioen AW,Duda DG.Anti-angiogenesis for cancer revisited:Is there a role for combinations with immunotherapy?[J].Angiogenesis,2017,20(2):185-204.
6 Saharinen P,Eklund L,Pulkki K,et al.Vegf and angiopoietin signaling in tumor angiogenesis and metastasis[J].Trends Mol Med,2011,17(7):347-362.
7 Mennitto A,Huber V,Ratta R,et al.Angiogenesis and immunity in renal carcinoma:Can we turn an unhappy relationship into a happy marriage?[J].J Clin Med,2020,9(4):930.
8 Kim HJ,Ji YR,Lee YM.Crosstalk between angiogenesis and immune regulation in the tumor microenvironment[J].Arch Pharm Res,2022,45(6):401-416.
9 Hack SP,Zhu AX,Wang Y.Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-l1 pathways:Challenges and opportunities[J].Front Immunol,2020,11:598877.
10 Lee WS,Yang H,Chon HJ,et al.Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity[J].Exp Mol Med,2020,52(9):1475-1485.
11 Rahma OE,Hodi FS.The intersection between tumor angiogenesis and immune suppression[J].Clin Cancer Res,2019,25(18):5449-5457.
12 Reck M,Mok TSK,Nishio M,et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(impower150):Key subgroup analyses of patients with egfr mutations or baseline liver metastases in a randomised,open-label phase 3 trial[J].Lancet Respir Med,2019,7(5):387-401.
13 Socinski MA,Jotte RM,Cappuzzo F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous nsclc[J].N Engl J Med,2018,378(24):2288-2301.
14 Lam TC,Tsang KC,Choi HC,et al.Combination atezolizumab,bevacizumab,pemetrexed and carboplatin for metastatic egfr mutated nsclc after tki failure[J].Lung Cancer,2021,159:18-26.
15 Sugawara S,Lee JS,Kang JH,et al.Nivolumab with carboplatin,paclitaxel,and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer[J].Ann Oncol,2021,32(9):1137-1147.
16 Rizvi NA,Antonia SJ,Shepherd FA,et al.Nivolumab(anti-PD-1;bms-936558,ono-4538)maintenance as monotherapy or in combination with bevacizumab(bev)for non-small cell lung cancer(nsclc)previously treated with chemotherapy[J].Int J Radiat Oncol,2014,90(5):32.
17 Kanda S,Goto K,Shiraishi H,et al.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer:a four arms phase Ⅰb study[J].Ann Oncol,2016,27(12):2242-2250.
18 Gadgeel SM,Stevenson JP,Langer CJ,et al.Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer:phase 1 cohorts from the keynote-021 study[J].Lung Cancer,2018,125:273-281.
19 Herbst RS,Arkenau HT,Santana-Davila R,et al.Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer,gastro-oesophageal cancer,or urothelial carcinomas(jvdf):A multicohort,non-randomised,open-label,phase 1a/b trial[J].Lancet Oncol,2019,20(8):1109-1123.
20 Herbst RS,Arkenau HT,Bendell J,et al.Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naïve nsclc[J].J Thorac Oncol,2021,16(2):289-298.
21 Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of vegfr2,pdgfrβ and fgfr1[J].Gene,2018,654:77-86.
22 Zhou CC,Gao GH,Ren SX,et al.Efficacy of PD-1 monoclonal antibody shr-1210 plus apatinib in patients with advanced non-squamous nsclc with wild-type egfr and alk[J].J Clin Oncol 2019,37:9112.
23 Zhou C,Wang Y,Zhao J,et al.Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous nsclc previously treated with chemotherapy[J].Clin Cancer Res,2021,27(5):1296-1304.
24 Gao G,Wang Y,Ren S,et al.1267p efficacy of camrelizumab(shr-1210)plus apatinib as second-line treatment for advanced squamous nsclc[J].Ann Oncol,2020,31:819.
25 Taylor MH,Lee CH,Makker V,et al.Phase Ⅰb/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma,endometrial cancer,and other selected advanced solid tumors[J].J Clin Oncol,2020,38(11):1154-1163.
26 Nishio M,Peled N,Zer A,et al.1313p phase Ⅲ leap-006 safety run-in(part 1):1l pembrolizumab(pembro)+ chemotherapy(chemo)with lenvatinib(len)for metastatic nsclc[J].Ann Oncol,2020,31:848-849.
27 Chu T,Zhong R,Zhong H,et al.Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced nsclc[J].J Thorac Oncol,2021,16(4):643-652.

[1]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[2]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[3]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[4]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[5]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[6]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[7]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[8]	WANG Junmei, PAN Huiqing, LI Jingyi, JIA Di, ZHAO Weiming, LV Changlian. The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma [J]. Journal of Practical Oncology, 2021, 35(3): 243-247.
[9]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[10]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[11]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[12]	DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(1): 64-68.
[13]	YAN Yan, HOU Lifang, LI Renfei, YAN Peng, WANG Yuedong, ZHENG Yuting. Imaging with ^99mTc-HYNIC-MPG molecular typing of non-small cell lung cancer in vivo [J]. Journal of Practical Oncology, 2020, 34(5): 412-417.
[14]	SUN Yajuan, JIANG Zhiyun, SHANG Naijian, SUN Qingxin, LU Peiou. Value of dual-source CT energy imaging in evaluating mediastinal lymph node metastasis in non-small cell lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 531-535.
[15]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.

Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments